← All trials
NCT05138484
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 20, 2017
- Primary completion
- Dec 17, 2018
- Completion date
- Jan 14, 2019
- First posted
- Dec 1, 2021
- Last posted
- Dec 1, 2021
- Enrollment
- 54
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidad Austral de ChileLead sponsor
- Pontificia Universidad Catolica de ChileOverall official - principal investigator
- Universidad Austral de ChileCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.